Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PRT3789 |
Synonyms | |
Therapy Description |
PRT3789 is a SMARCA2 degrader, which potentially decreases proliferation of tumor cells with SMARCA4 loss and inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3263). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRT3789 | PRT-3789|PRT 3789 | PRT3789 is a SMARCA2 degrader, which potentially decreases proliferation of tumor cells with SMARCA4 loss and inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3263). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
SMARCA4 del | lung non-small cell carcinoma | predicted - sensitive | PRT3789 | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, PRT3789 inhibited proliferation of non-small cell lung cancer cells with deletion of SMARCA4 in culture and inhibited tumor growth in cell line xenograft and patient-derived xenograft (PDX) models (Cancer Res 2022;82(12_Suppl):Abstract nr 3263). | detail... |
SMARCA4 mutant | lung non-small cell carcinoma | predicted - sensitive | PRT3789 | Phase I | Actionable | In a Phase I trial, PRT3789 treatment was well tolerated and resulted in partial responses, tumor shrinkage, and prolonged stable disease in patients with advanced esophageal cancer (N=2) or non-small cell lung cancer (N=18) harboring SMARCA4 mutations (Ann Oncol (2024) 35 (suppl_2): S483-S484; NCT05639751). | detail... |
SMARCA4 mutant | esophageal cancer | predicted - sensitive | PRT3789 | Case Reports/Case Series | Actionable | In a Phase I trial, PRT3789 treatment was well tolerated and resulted in partial responses, tumor shrinkage, and prolonged stable disease in patients with advanced esophageal cancer (N=2) or non-small cell lung cancer (N=18) harboring SMARCA4 mutations (Ann Oncol (2024) 35 (suppl_2): S483-S484; NCT05639751). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05639751 | Phase I | Docetaxel + PRT3789 PRT3789 | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | Recruiting | USA | NLD | FRA | ESP | 1 |